Edgar Filing: ANTIGENICS INC /DE/ - Form 4

ANTIGENIC	CS INC /DE/										
Form 4 July 06, 2006											
FORM	Л	CT A TEC	SECU			CHANCE	E COMMISSIO	NT.	PPROVAL		
	N OMB Number:	3235-0287									
Check this box if no longer subject to Section 16. Form 4 or								Expires: Estimated burden hou response	urs per		
Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section See Instruction 1(b). See Instruction											
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> AFEYAN NOUBAR			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
			ANTIGENICS INC /DE/ [AGEN]				(Check all applicable)				
(Last) 1 SUNSET I		(Middle)	 3. Date of Earliest Transaction (Month/Day/Year) 07/03/2006 				X_ Director 10% Owner Officer (give title Other (specify below) below)				
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					1	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
LEXINGTO	N, MA 02173						Person		eportung		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D) Price	(Instr. 3 and 4)				
Reminder: Repo	ort on a separate line	e for each cla	ass of sec	urities bene	-	-	-				
					inforn requii	nation cont ed to resp lys a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A) or		

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

Derivative Security				Disposed of (D) (Instr. 3, 4, and 5)						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Shares (1)	<u>(1)</u>	07/03/2006	А		3,301.145		<u>(1)</u>	<u>(1)</u>	Common Stock	3,301.14

Reporting Owners

Reporting Owner Name / Address		Relationsh	iips			
I B	Director	10% Owner	Officer	Other		
AFEYAN NOUBAR 1 SUNSET RIDGE LEXINGTON, MA 02173	Х					
Signatures						
Christine M. Klaskin, by Powe Attorney	r of	07/	/06/2006	5		
**Signature of Reporting Person			Date			
Evaluation of Responses:						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Acquired under the Antigenics Inc. Directors' Deferred Compensation Plan. Deferred shares represent an equal amount of shares of the
 (1) Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.